The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients

Hakimi,M.; Hyhlik-Dürr,A.; von Au,A.; Betz,M.; Demirel,S.; Dihlmann,S.; Böckler,D.; Gross-Weissmann,M.  L.

doi:10.3892/ijmm.2013.1401

The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients

Authors:
- M. Hakimi
- A. Hyhlik-Dürr
- A. von Au
- M. Betz
- S. Demirel
- S. Dihlmann
- D. Böckler
- M. L. Gross-Weissmann
View Affiliations

Affiliations: Department of Vascular Surgery, University of Heidelberg, D-69120 Heidelberg, Germany, Institute of Pathology, University of Heidelberg, D-69120 Heidelberg, Germany
Published online on: May 30, 2013 https://doi.org/10.3892/ijmm.2013.1401
Pages: 331-338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate in detail the histopathological characteristics of endarterectomized carotid atherosclerotic lesions in symptomatic versus asymptomatic patients. Twenty carotid lesions, 10 from asymptomatic and 10 from symptomatic patients who underwent carotid endarterectomy were classified according to histomorphological features. Samples were analyzed for intraplaque localization and for the expression of proteins associated with inflammation, such as CD68, interleukin (IL)-1β, tumor necrosis factor‑α (TNF-α), pentraxin-3 (PTX‑3), nuclear factor‑κB (NF-κB), C-reactive protein (CRP) and transforming growth factor-β (TGF-β), as well as for proteins associated with vascular remodelling, such as matrix-metalloproteinase-9 (MMP-9), glycophorin A (GYPA), osteoprotegerin (OPG), vascular cell adhesion molecule‑1 (VCAM-1), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) and vascular smooth muscle cell actin (VSMA). Corresponding expression scores were compared between the symptomatic and asymptomatic patients and evaluated statistically. The expression of all 14 evaluated markers was significantly elevated in the border zone adjacent to the mixed plaque compared with the unaffected control area of the same sample (p<0,016). The expression scores of GYPA and OPG were significantly higher in the border zones around the calcified (GYPA, p=0.035; OPG, p=0.043) and mixed (GYPA, p<0.001; OPG, p=0.007) plaque zones of symptomatic patients compared to asymptomatic patients. No difference in expression scores was observed for any of the analyzed inflammatory marker proteins between the border zones of symptomatic and asymptomatic patients. In conclusion, the increased expression of GYPA, indicating intraplaque hemorrhage, and OPG, indicating the transdifferentiation of vascular cells, in carotid atherosclerotic lesions may be associated with an increased risk of plaque instability.

View Figures

View References

1	Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 325:445–453. 1991. View Article : Google Scholar : PubMed/NCBI
2	Halliday AW, Thomas DJ and Mansfield AO: The asymptomatic carotid surgery trial (ACST). Int Angiol. 14:18–20. 1995.
3	Golledge J: Carotid intervention in asymptomatic patients. Stroke. 39:e172008. View Article : Google Scholar
4	Mauriello A, Sangiorgi GM, Virmani R, et al: A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis. 208:572–580. 2010. View Article : Google Scholar : PubMed/NCBI
5	Galis ZS, Sukhova GK, Lark MW and Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:2493–2503. 1994. View Article : Google Scholar
6	Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
7	Kolodgie FD, Gold HK, Burke AP, et al: Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 349:2316–2325. 2003. View Article : Google Scholar : PubMed/NCBI
8	Abedin M, Omland T, Ueland T, et al: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 99:513–518. 2007. View Article : Google Scholar : PubMed/NCBI
9	Golledge J, McCann M, Mangan S, Lam A and Karan M: Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 35:1636–1641. 2004. View Article : Google Scholar : PubMed/NCBI
10	Adams DH and Shaw S: Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 343:831–836. 1994. View Article : Google Scholar : PubMed/NCBI
11	Ramana KV, Bhatnagar A and Srivastava SK: Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J. 18:1209–1218. 2004. View Article : Google Scholar : PubMed/NCBI
12	Bevilacqua MP: Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 11:767–804. 1993. View Article : Google Scholar : PubMed/NCBI
13	Cybulsky MI and Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:788–791. 1991. View Article : Google Scholar : PubMed/NCBI
14	Stephan CC and Brock TA: Vascular endothelial growth factor, a multifunctional polypeptide. P R Health Sci J. 15:169–178. 1996.PubMed/NCBI
15	O’Brien ER, Garvin MR, Dev R, et al: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 145:883–894. 1994.
16	Schiffrin EL and Touyz RM: Vascular biology of endothelin. J Cardiovasc Pharmacol. 32(Suppl 3): S2–S13. 1998.
17	Soeki T, Niki T, Kusunose K, et al: Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol. 58:151–157. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bisoendial RJ, Birjmohun RS, Akdim F, et al: C-reactive protein elicits white blood cell activation in humans. Am J Med. 122:582 e1–e9. 2009.PubMed/NCBI
19	Zeibig S, Li Z, Wagner S, et al: Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circ Res. 108:695–703. 2011. View Article : Google Scholar : PubMed/NCBI
20	Artese L, Ucchino S, Piattelli A, et al: Factors associated with apoptosis in symptomatic and asymptomatic carotid atherosclerotic plaques. Int J Immunopathol Pharmacol. 18:645–653. 2005.PubMed/NCBI
21	Stary HC, Chandler AB, Dinsmore RE, et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 15:1512–1531. 1995. View Article : Google Scholar
22	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German).
23	Gross ML, Meyer HP, Ziebart H, et al: Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2:121–134. 2007. View Article : Google Scholar
24	Verstraete M: Coronary atherosclerosis and thrombosis. Recenti Prog Med. 81:221–227. 1990.
25	Slevin M, Wang Q, Font MA, et al: Atherothrombosis and plaque heterology: different location or a unique disease? Pathobiology. 75:209–225. 2008. View Article : Google Scholar : PubMed/NCBI
26	Aidinian G, Weiswasser JM, Arora S, Abularrage CJ, Singh N and Sidawy AN: Carotid plaque morphologic characteristics. Perspect Vasc Surg Endovasc Ther. 18:63–70. 2006. View Article : Google Scholar : PubMed/NCBI
27	Naghavi M, Libby P, Falk E, et al: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 108:1664–1672. 2003. View Article : Google Scholar
28	Kher N and Marsh JD: Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost. 30:665–672. 2004. View Article : Google Scholar : PubMed/NCBI
29	Stary HC, Chandler AB, Dinsmore RE, et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 92:1355–1374. 1995. View Article : Google Scholar
30	Koenig W and Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 27:15–26. 2007. View Article : Google Scholar : PubMed/NCBI
31	Fagerberg B, Ryndel M, Kjelldahl J, et al: Differences in lesion severity and cellular composition between in vivo assessed upstream and downstream sides of human symptomatic carotid atherosclerotic plaques. J Vasc Res. 47:221–230. 2010. View Article : Google Scholar
32	Wahlgren CM, Zheng W, Shaalan W, Tang J and Bassiouny HS: Human carotid plaque calcification and vulnerability. Relationship between degree of plaque calcification, fibrous cap inflammatory gene expression and symptomatology. Cerebrovasc Dis. 27:193–200. 2009.
33	Libby P, Ridker PM and Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 54:2129–2138. 2009. View Article : Google Scholar : PubMed/NCBI
34	Hao H, Iihara K, Ishibashi-Ueda H, Saito F and Hirota S: Correlation of thin fibrous cap possessing adipophilin-positive macrophages and intraplaque hemorrhage with high clinical risk for carotid endarterectomy. J Neurosurg. 114:1080–1087. 2011. View Article : Google Scholar : PubMed/NCBI
35	Van Campenhout A and Golledge J: Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 204:321–329. 2009.PubMed/NCBI
36	Schoppet M, Al-Fakhri N, Franke FE, et al: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab. 89:4104–4112. 2004.